Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Number of Triptans Previously Tried and Failed

被引：0

作者：

Jensen, C. M. ^{[1
]}

Lipton, R. B. ^{[2
]}

Blumenfeld, A. M. ^{[3
]}

Croop, R. ^{[1
]}

Thiry, A. ^{[1
]}

L'Italien, G. ^{[1
]}

Morris, B. ^{[1
]}

Coric, V. ^{[1
]}

Goadsby, P. J. ^{[4
,5
]}

机构：

[1] Biohaven Pharmaceut, New Haven, CT USA

[2] Albert Einstein Coll Med, Bronx, NY 10467 USA

[3] Headache Ctr Southern Calif, Carlsbad, CA USA

[4] Kings Coll, NIHR Wellcome Trust Kings Clin Res Facil, Kings Coll Hosp SLaM Biomed Res Ctr, London, Germany

[5] Univ Calif Los Angeles, Los Angeles, CA USA

来源：

JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P0268

引用

页码：99 / 100

页数：2

共 50 条

[1] Rimegepant for the acute treatment of migraine: Subgroup analyses from 3 phase 3 clinical trials by number of triptans previously tried and failed
Lipton, R. B.
Blumenfeld, A. M.
Jensen, C. M.
Croop, R.
Thiry, A. C.
L'Italien, G. J.
Morris, B. A.
Coric, V
Goadsby, P. J.
[J]. HEADACHE, 2021, 61 : 144 - 145
[2] Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Number of Triptans Previously Tried and Failed
Jensen, C. M.
Lipton, R. B.
Blumenfeld, A. M.
Croop, R.
Thiry, A.
L'Italien, G.
Morris, B.
Coric, V.
Goadsby, P. J.
[J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 148 - 148
[3] Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
Jensen, Christopher M.
Lipton, Richard B.
Blumenfeld, Andrew
Croop, Robert
Thiry, Alexandra
L'Italien, Gilbert
Morris, Beth A.
Coric, Vladimir
Goadsby, Peter J.
[J]. CEPHALALGIA, 2022, 42 (1_SUPPL) : 116 - 117
[4] Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
Jensen, C. M.
Lipton, R.
Blumenfeld, A.
Croop, R.
Thiry, A. C.
L'Italien, G.
Morris, B.
Coric, V.
Goadsby, P.
[J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[5] Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Who Have Discontinued or Currently Use Triptans: Results From 3 Phase 3 Clinical Trials
Lipton, R. B.
Blumenfeld, A. M.
Croop, R.
Jensen, C. M.
Thiry, A. C.
Stock, E. G.
Conway, C. M.
Morris, B. A.
Coric, V
Goadsby, P. J.
[J]. HEADACHE, 2020, 60 : 121 - 122
[6] Rimegepant is Effective for the Acute Treatment of Migraine in Patients Who Have Discontinued or Currently Use Triptans: Results from 3 Phase 3 Clinical Trials
Croop, Robert
Jensen, Christopher
Thiry, Alexandra
Stock, Elyse
Conway, Charles
Morris, Beth
Coric, Vladimir
Lipton, Richard
[J]. NEUROLOGY, 2020, 94 (15)
[7] Rimegepant for the Acute Treatment of Migraine in Patients with a History of Triptan Treatment Failure: Pooled Results From 3 Phase 3 Clinical Trials
Jensen, Christopher
Lipton, Richard
Blumenfeld, Andrew
Croop, Robert
Thiry, Alexandra
L'Italien, Gilbert
Morris, Beth
Coric, Vlad
Goadsby, Peter
[J]. NEUROLOGY, 2021, 96 (15)
[8] Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
Knievel, Kerry
Buchanan, Andrew S.
Lombard, Louise
Baygani, Simin
Raskin, Joel
Krege, John H.
Loo, Li Shen
Komori, Mika
Tobin, Joshua
[J]. CEPHALALGIA, 2020, 40 (01) : 19 - 27
[9] Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials
Dodick, David W.
Pavlovic, Jelena M.
Newman, Lawrence C.
Lipton, Richard B.
Thiry, Alexandra
Morris, Beth A.
Coric, Vladimir
Croop, Robert
[J]. CEPHALALGIA, 2019, 39 : 188 - 189
[10] Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials
Levin, Morris
Buse, Dawn
Blumenfeld, Andrew
Lipton, Richard
Stock, Elyse
Thiry, Alexandra
Conway, Charlie
Jensen, Christopher
Morris, Beth
Coric, Vladimir
Croop, Robert
[J]. NEUROLOGY, 2020, 94 (15)

← 1 2 3 4 5 →